China Oncology ›› 2022, Vol. 32 ›› Issue (2): 152-160.doi: 10.19401/j.cnki.1007-3639.2022.02.007
Previous Articles Next Articles
HOU Qinghua1,2, ZHONG Yanfeng3, LIU Linzhuang2, WU Liusheng2, LIU Jixian2()
Received:
2021-11-28
Revised:
2022-01-28
Online:
2022-02-28
Published:
2022-03-08
Contact:
LIU Jixian
E-mail:252110465@qq.com
CLC Number:
HOU Qinghua, ZHONG Yanfeng, LIU Linzhuang, WU Liusheng, LIU Jixian. Expression, prognostic value of CBX3 in lung adenocarcinoma and its effect on biological behavior of cancer cells[J]. China Oncology, 2022, 32(2): 152-160.
Tab. 1
Clinicopathological features of lung adenocarcinoma with differential expression of CBX3"
Characteristic* | Low expression of CBX3 | High expression of CBX3 | P value |
---|---|---|---|
T stage n (%) | 0.031 | ||
T1 | 97 (19.0) | 71 (13.9) | |
T2 | 126 (24.7) | 150 (29.4) | |
T3 | 25 (4.9) | 22 (4.3) | |
T4 | 6 (1.2) | 13 (2.5) | |
N stage n (%) | 0.005 | ||
N0 | 179 (35.7) | 151 (30.1) | |
N1 | 42 (8.4) | 53 (10.6) | |
N2 | 26 (5.2) | 48 (9.6) | |
N3 | 0 (0.0) | 2 (0.4) | |
M stage n (%) | 0.342 | ||
M0 | 165 (44.7) | 179 (48.5) | |
M1 | 9 (2.4) | 16 (4.3) | |
Pathologic stage n (%) | 0.102 | ||
Ⅰ | 148 (29.3) | 126 (25.0) | |
Ⅱ | 60 (11.9) | 61 (12.1) | |
Ⅲ | 34 (6.7) | 50 (9.9) | |
Ⅳ | 10 (2.0) | 16 (3.2) | |
Gender n (%) | 0.504 | ||
Female | 142 (27.7) | 134 (26.1) | |
Male | 114 (22.2) | 123 (24.0) | |
Age/year n (%) | 0.024 | ||
≤65 | 105 (21.3) | 133 (26.9) | |
>65 | 140 (28.3) | 116 (23.5) | |
Smoker n (%) | 0.368 | ||
No | 41 (8.2) | 33 (6.6) | |
Yes | 208 (41.7) | 217 (43.5) |
Fig. 2
CBX3 overexpression and immune infiltration and immune cell infiltration of the top 4 immune cells with CBX3 correlation score AA: Correlation between different cells; B-E: The enrichment of helper T cell 2 cell (Th2) cells, mast cells, eosinophils, and iDC cells with CBX3 correlation score."
Fig. 3
The predictive value of CBX3 expression in diagnosis and clinical prognosis of patients with lung adenocarcinomaA: Receiver operating characteristic (ROC) curve analysis of CBX3 in diagnosis of lung adenocarcinoma; B: Kaplan-Meier analysis of disease-specific survival of overall survival, between the high and low expression groups of CBX3; C: Progression-free survival; D: Disease-specific survival."
[1] | SUNG H,, FERLAY J,, SIEGEL R L, et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. |
[2] | HUTCHINSON B D,, SHROFF G S,, TRUONG M T, et al.Spectrum of lung adenocarcinoma[J]. Semin Ultrasound CT MR, 2019, 40(3): 255-264. |
[3] | ETTINGER D S,, WOOD D E,, AISNER D L, et al.Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2017, 15(4): 504-535. |
[4] | OSMANI L,, ASKIN F,, GABRIELSON E, et al.Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): moving from targeted therapy to immunotherapy[J]. Semin Cancer Biol, 2018, 52(Pt 1): 103-109. |
[5] | XING P Y,, WANG S Z,, WANG Q, et al.Efficacy of crizotinib for advanced ALK-rearranged non-small cell lung cancer patients with brain metastasis: a multicenter, retrospective study in China[J]. Target Oncol, 2019, 14(3): 325-333. |
[6] | 王晓莉,, 葛晓松,, 刘彦魁, 等. EGFR/ALK/ROS1三联检测在非小细胞肺癌中的临床意义[J]. 临床与实验病理学杂志, 2018, 34(10): 1135-1137. |
WANG X L,, GE X S,, LIU Y K, et al.Clinical significance of EGFR/ALK/ros1 triple detection in non-small cell lung cancer[J]. Chin J Clin Exp Pathol, 2018, 34(10): 1135-1137. | |
[7] | PARK J Y,, JANG S H.Epidemiology of lung cancer in Korea: recent trends[J]. Tuberc Respir Dis (Seoul), 2016, 79(2): 58-69. |
[8] | TESTA U,, CASTELLI G,, PELOSI E.Lung cancers: molecular characterization, clonal heterogeneity and evolution, and cancer stem cells[J]. Cancers (Basel), 2018, 10(8): E248. |
[9] | CHANG S C,, LAI Y C,, CHEN Y C, et al.CBX3/heterochromatin protein 1 gamma is significantly upregulated in patients with non-small cell lung cancer[J]. Asia Pac J Clin Oncol, 2018, 14(5): e283-e288. |
[10] | CANZIO D,, LARSON A,, NARLIKAR G J.Mechanisms of functional promiscuity by HP1 proteins[J]. Trends Cell Biol, 2014, 24(6): 377-386. |
[11] | LOVE M I,, HUBER W,, ANDERS S.Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2[J]. Genome Biol, 2014, 15(12): 550. |
[12] | HÄNZELMANN S,, CASTELO R,, GUINNEY J. GSVA: gene set variation analysis for microarray and RNA-seq data[J]. BMC Bioinformatics, 2013, 14: 7. |
[13] | BINDEA G,, MLECNIK B,, TOSOLINI M, et al.Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer[J]. Immunity, 2013, 39(4): 782-795. |
[14] | CHALELA R,, CURULL V,, ENRÍQUEZ C, et al. Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy[J]. J Thorac Dis, 2017, 9(7): 2142-2158. |
[15] | IMAI H,, KAIRA K,, MINATO K.Clinical significance of post-progression survival in lung cancer[J]. Thorac Cancer, 2017, 8(5): 379-386. |
[16] | GREWAL S I,, JIA S.Heterochromatin revisited[J]. Nat Rev Genet, 2007, 8(1): 35-46. |
[17] | VAKOC C R,, MANDAT S A,, OLENCHOCK B A, et al.Histone H3 lysine 9 methylation and HP1gamma are associated with transcription elongation through mammalian chromatin[J]. Mol Cell, 2005, 19(3): 381-391. |
[18] | MATEESCU B,, BOURACHOT B,, RACHEZ C, et al.Regulation of an inducible promoter by an HP1beta-HP1gamma switch[J]. EMBO Rep, 2008, 9(3): 267-272. |
[19] | KWON S H,, WORKMAN J L.HP1c casts light on dark matter[J]. Cell Cycle, 2011, 10(4): 625-630. |
[20] | NONAKA N,, KITAJIMA T,, YOKOBAYASHI S, et al.Recruitment of cohesin to heterochromatic regions by Swi6/HP1 in fission yeast[J]. Nat Cell Biol, 2002, 4(1): 89-93. |
[21] | YAMAGISHI Y,, SAKUNO T,, SHIMURA M, et al.Author correction: heterochromatin links to centromeric protection by recruiting shugoshin[J]. Nature, 2018, 563(7730): E21. |
[22] | HAYAKAWA T,, HARAGUCHI T,, MASUMOTO H, et al.Cell cycle behavior of human HP1 subtypes: distinct molecular domains of HP1 are required for their centromeric localization during interphase and metaphase[J]. J Cell Sci, 2003, 116(Pt 16): 3327-3338. |
[23] | EGUCHI T,, CALDERWOOD S K,, TAKIGAWA M, et al.Intracellular MMP3 promotes HSP gene expression in collaboration with chromobox proteins[J]. J Cell Biochem, 2017, 118(1): 43-51. |
[24] | FAN Y,, LI H P,, LIANG X L, et al.CBX3 promotes colon cancer cell proliferation by CDK6 kinase-independent function during cell cycle[J]. Oncotarget, 2017, 8(12): 19934-19946. |
[25] | WANG S Q,, LIU F,, WANG Y H, et al.Integrated analysis of 34 microarray datasets reveals CBX3 as a diagnostic and prognostic biomarker in glioblastoma[J]. J Transl Med, 2019, 17(1): 179. |
[26] | HAN S S,, KIM W J,, HONG Y, et al.RNA sequencing identifies novel markers of non-small cell lung cancer[J]. Lung Cancer, 2014, 84(3): 229-235. |
[27] | LIU J,, ZHANG Y,, ZHAO J, et al.Mast cell: insight into remodeling a tumor microenvironment[J]. Cancer Metastasis Rev, 2011, 30(2): 177-184. |
[28] | HUANG B,, LEI Z,, ZHANG G M, et al.SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment[J]. Blood, 2008, 112(4): 1269-1279. |
[1] | MA Yifei , LIANG Xinjun , WEI Shaozhong . Prognostic value of inflammatory and immune markers in resectable colorectal cancer [J]. China Oncology, 2021, 31(9): 845-851. |
[2] | LEI Yajie , GAO Yi , WANG Zhijie , CHENG Xi , YANG Yufei , ZHOU Hongyu , CHEN Lihua , CHEN Yixin , LI Haoran , LI Ziting , WU Xiaohua . Potential role of lymphadenectomy in patients with ovarian cancer (ⅠC-ⅡA): a retrospective trial [J]. China Oncology, 2021, 31(8): 740-745. |
[3] | GAO Heli, XU Jin, YU Xianjun. Advances in clinical diagnosis and treatment of gastroenteropancreatic neuroendocrine tumor G3 [J]. China Oncology, 2021, 31(7): 567-573. |
[4] | HU Guannan , CHEN Lei , ZHOU Liangping , ZHOU Zhengrong . A case report of pulmonary malignant melanoma complicated with lung adenocarcinoma and literature review [J]. China Oncology, 2021, 31(7): 647-650. |
[5] | HU Yaqiong , BAI Jun , CHEN Lin , CHEN Xinlu , ZHANG Liping , ZHOU Dandan , WANG Yu , YIN Chonggao , LI Hongli , LIU Yuqing . miR-625-5p promotes proliferation and invasion of lung adenocarcinoma by targeting PRKACA [J]. China Oncology, 2021, 31(6): 447-454. |
[6] | GONG Runze, HU Haiyan. Clinical significance of CCL2 expression in osteosarcoma tissue [J]. China Oncology, 2021, 31(6): 455-459. |
[7] | PENG Zishan, KONG Hui, BAO Zhen, ZHAO Hongxing, LIU Xin, LU Shaohua. Clinicopathological analysis of 83 cases of multifocal lung adenocarcinoma [J]. China Oncology, 2021, 31(5): 408-418. |
[8] | XIAO Feng , XIAO Jingwen , SHAO Jianguo , CHEN Liyan , GU Chunyan . The expression of programmed death 1 in tumor-infiltrating lymphocytes of hepatocellular carcinoma and its correlation with prognosis [J]. China Oncology, 2021, 31(5): 419-427. |
[9] | SHI Maolin , BAI Yudi , WANG Chao , LI Siqi , ZHOU Daijun , PENG Jingjing , SUN Feifan , LI Dong , ZHANG Tao . Effect of PD-L1 expression on the efficacy of pemetrexed-based chemotherapy in patients with advanced lung adenocarcinoma and its mechanism [J]. China Oncology, 2021, 31(4): 308-316. |
[10] | WANG Chunjian , NIE Gang , MAO Yan . The role of TRIP6 in breast cancer and its mechanism [J]. China Oncology, 2021, 31(3): 161-169. |
[11] | WU Yuanyuan , WANG Jun , LIU Qinjiang , ZHANG Ming . Analysis of prognostic factors and treatment strategies of anaplastic thyroid carcinoma [J]. China Oncology, 2021, 31(3): 212-220. |
[12] | YANG Liusong , ZHU Yingfeng , TANG Jianmin . Ten cases of epithelioid glioblastoma and review of literature [J]. China Oncology, 2021, 31(2): 114-120. |
[13] | DING Ping’an , ZHANG Zhidong , YANG Peigang , LIN Yecheng , TIAN Yuan , XU Xiaosheng , WU Juan , LIU Ying , GUO Honghai , LIU Yang , WANG Dong , TAN Bibo , LI Yong , ZHAO Qun . Clinicopathological characteristics and prognostic analysis of leptomeningeal metastasis from gastric cancer [J]. China Oncology, 2021, 31(2): 126-135. |
[14] | ZHOU Hongyu , LI Haoran , CHENG Xi , CHEN Lihua , YANG Yufei , CHANG Bin . Clinical characteristics of 11 patients with small cell carcinoma of the ovary, hypercalcemic type and literature review [J]. China Oncology, 2021, 31(2): 136-142. |
[15] | LI Fei , SONG Yuan , LI Fang , ZHU Xiyang , HE Ming . Treatment effect of thoracic surgery for Siewert type Ⅰ and type Ⅱ adenocarcinoma of the esophagogastric junction and prognostic study [J]. China Oncology, 2021, 31(2): 143-150. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd